Source: Research Seminar 2008 - Host-pathogen interactions in the lung: implications for treatment of respiratory infections and inflammatory lung diseases
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
P. Hiemstra (Leiden, The Netherlands). Antimicrobial peptides. Research Seminar 2008 - Host-pathogen interactions in the lung: implications for treatment of respiratory infections and inflammatory lung diseases

Member's Comments

No comment yet.

Related content which might interest you: Antimicrobial susceptibility of atypical pathogens Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 Antimicrobial peptides and airway bacterial colonization in bronchiectasis Source: International Congress 2018 – Bronchiectasis: phenotypes, endotypes and new therapies Year: 2018 Treatment of difficult Gram-positive infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=113 Year: 2004 Antimicrobial resistance and new therapeutic options Source: Virtual Congress 2021 – Community-acquired pneumonia: the new perspective in the post-COVID era Year: 2021 Antimicrobial resistance in respiratory diseases Source: International Congress 2019 – Fighting antimicrobial resistance: from prevention to antimicrobial stewardship Year: 2019 Antimicrobial peptides in induced sputum of asthmatic patients Source: Eur Respir J 2005; 26: Suppl. 49, 484s Year: 2005 The antimicrobial peptide CRAMP protects against emphysema Source: Annual Congress 2012 - Cell culture and animal models of lung disease Year: 2012 Potential antimicrobial agents for the treatment of multidrug-resistant tuberculosis Source: Eur Respir J 2014; 43: 884-897 Year: 2014 Antimicrobial susceptibility of pseudomonasaeruginosa in CF patients before and after regular treatment with inhaled tobramycin Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015 Antimicrobial Treatment of CAP. Is there a higher benefit of macrolides combination in patients with pneumococcal CAP? Source: International Congress 2017 – Update on community acquired pneumonia Year: 2017 Minimum inhibitory concentrations (MIC) determination of TB drugs and broad-spectrum antibiotics in M.tuberculosis with M/X/TDR Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Antibiotic stewardship Source: Annual Congress 2012 - Infection control of respiratory pathogens Year: 2012 Antimicrobial peptides in the real world: implications for cystic fibrosis Source: Eur Respir J 2007; 29: 617-618 Year: 2007 Staphlococcus aureus: susceptibility to antibacterial drugs and rate of MRSA Source: Eur Respir J 2006; 28: Suppl. 50, 788s Year: 2006 The antimicrobial molecule elafin protects the lung against Staphylococcus aureus infection Source: Annual Congress 2004 - Community acquired pneumonia - epidemiology and host defence Year: 2004 Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use Source: Eur Respir J, 50 (6) 1701633; 10.1183/13993003.01633-2017 Year: 2017